CTOs on the Move

DeGolers Pharmacies

www.degoler.com

 
DeGolers Pharmacies is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.degoler.com
  • 7622 State Ave
    Kansas City, KS USA 66112
  • Phone: 913.596.2447

Executives

Name Title Contact Details

Similar Companies

Pfizer

97250 Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City.

Bio Pharma Services Inc

Bio Pharma Services Inc is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Good Samaritan Health Center of Gwinnett

The Good Samaritan Health Center of Gwinnett is a non-profit medical clinic whose mission is to demonstrate the love of Christ by providing low-cost primary care, dental care, and disease management services for uninsured residents of the north metro A...

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.